

CF

End Stage Renal Disease Program

Health Care Financing Administration

Instruction Manual for Renal Providers



U.S. Department of Health and Human Services

Otis R. Bowen, M.D., *Secretary*

Health Care Financing Administration

William L. Roper, M.D., *Administrator*

Bureau of Data Management and Strategy

Regina McPhillips, Dr. P.H., *Director*

David G. Butler, *Deputy Director*

Office of Statistics and Data Management

Michael R. McMullan, *Director*

Division of Information Analysis

Charles R. Fisher, *Director*

End Stage Renal Disease Information Analysis Branch

M. Zerman Breidenbaugh, *Chief*

End Stage Renal Disease Program

Health Care Financing Administration

Instruction Manual for Renal Providers

Program Management and Medical Information System

U.S. Department of Health and Human Services
Health Care Financing Administration
Bureau of Data Management and Strategy
Baltimore, Maryland
February 1989

Purpose of Manual

The *Instruction Manual for Renal Providers* was created to assist Medicare-approved renal providers in preparing and submitting the nonreimbursement end stage renal disease data collection forms necessary to the operation of the national ESRD Program Management and Medical Information System (PMMIS). Completion and submission of these forms are required by law (section 405.2133 of Subpart U of the *Code of Federal Regulations*).

Contents

Description of ESRD data collection forms	1
ESRD forms to be submitted to network offices	2
Chronic Renal Disease Medical Evidence Report, HCFA-2728-U4	3
ESRD Facility Survey, HCFA-2744	13
ESRD Transplant Information, HCFA-2745-U4	31
ESRD Transplant Follow-up Form	42
ESRD Death Notification, HCFA-2746	52

Appendices

ESRD Network Map	57
ICD9CM Codes and Narratives	58

DESCRIPTION OF ESRD DATA COLLECTION FORMS

The forms described in this Manual are utilized to gather data for the End Stage Renal Disease (ESRD) Program Management and Medical Information System (PMMIS). All Medicare-approved renal providers are required by law (section 405.2133 of Subpart U of the Code of Federal Regulations) to complete these forms on a timely basis.

These forms are listed below.

HCFA-2728-U4, Chronic Renal Disease Medical Evidence Report

This form is to be completed once the patient is diagnosed as having end stage renal disease. It requires a physician's signature certifying that the patient has ESRD. The information captured from this form will identify new patients filing for ESRD Medicare benefits. This form is available from the local social security office or the social worker at the renal provider.

HCFA-2744, ESRD Facility Survey

This form is completed annually by all Medicare-approved renal providers. This form is sent to each provider by the Network office.

HCFA-2745-U4, ESRD Transplant Information

This form is completed by all Medicare-approved renal transplant providers within 2 weeks of the date of transplant. These forms should be available at all transplant providers; if not, they may be obtained by calling the Network office.

Transplant Follow-up Form

This form is initially completed by all Medicare-approved renal transplant providers at the time the transplant recipient is discharged from the hospital following the transplant surgery. These Follow-ups are to be completed by the transplant provider or attending physician, if different from the transplant surgeon. Transplant Follow-ups must be completed as long as the patient lives and the transplanted kidney functions. Subsequent Transplant Follow-ups are to be completed 6 months post-transplant, 1 year post transplant, and yearly thereafter. These forms should be available at all transplant providers; if not, they may be obtained by calling the Network office.

HCFA-2746, ESRD Death Notification

This form is completed by the primary provider of care within 2 weeks of the date of death of an ESRD patient, regardless of where the death occurred. These forms should be available at all Medicare-approved renal providers; if not, they may be obtained by calling the Network office.

ESRD FORMS TO BE SUBMITTED TO THE NETWORK OFFICES

Form	Completed By	When to Complete	Where to Submit Copies of Forms
HCFA-2728-U4 Chronic Renal Disease Medical Evidence Report	Attending physician	Once the patient is diagnosed as having ESRD	WHITE copy: Send to servicing social security office BLUE and YELLOW copies: Send to network GREEN copy: Retain in provider
HCFA-2744 ESRD Facility Survey	Transplant centers and dialysis units	Annually	Send completed Survey to network
HCFA-2745-U4 ESRD Transplant Information	Transplant centers	Within 2 weeks following date of transplant	PINK and YELLOW copies: Send to network WHITE copy: Retain in provider GREEN copy: Send to Medicare specialty carrier
ESRD Transplant Follow-up Form	Transplant centers initially; transplant centers or attending physicians subsequently	At time of discharge from hospital following transplant surgery; at 6 months post-transplant; at 1 year post-transplant; yearly thereafter (until patient dies, the transplanted kidney fails or the patient is lost-to-follow-up)	Send completed form to network
HCFA-2746 ESRD Death Notification	Transplant center or dialysis unit which was last responsible for care of patient on an ongoing basis, regardless of place of death	Within 2 weeks following date of death	GREEN and YELLOW copies: Send to network WHITE copy: Retain in provider

The completed forms will be verified by network staff and questionable items will be resolved before the network sends the data to the ESRD Support Section within the Health Care Financing Administration.

The Chronic Renal Disease Medical Evidence Report, HCFA-2728-U4, is to be completed once the patient is diagnosed as having end stage renal disease (ESRD). It requires a physician's signature certifying that the patient has ESRD. The information captured from this report will identify new patients filing for ESRD Medicare benefits. (See note below.)

The original (WHITE) copy is to be sent to the local servicing social security office.

The second (BLUE) and third (YELLOW) copies are to be sent to the network office. The network will forward the blue copy to the ESRD Support Section and will retain the yellow copy for its files.

The fourth (GREEN) copy is to be retained by the provider.

NOTE: The HCFA-2728-U4 is a Medicare entitlement form. In addition, it provides medical data for the PMMIS. Listed below are various situations covering the completion/submission of the initial or subsequent HCFA-2728-U4.

1. An initial HCFA-2728-U4 must be completed and submitted on every newly diagnosed ESRD patient, including those who may already be entitled to Medicare based on old-age or disability.
2. A second HCFA-2728-U4 must be completed on an ESRD patient who, having had a "successful" kidney transplant for 36 months or longer (and, therefore, terminated for Medicare ESRD purposes), must return to dialysis because of transplant failure (i.e., must reapply for Medicare based on ESRD).
3. A second HCFA-2728-U4 need not be completed for an ESRD patient who receives a transplant or enters a self-dialysis training course after the 3-month qualifying period has passed. However, if the transplant or self-dialysis training occurs during the qualifying period, the ESRD patient may be eligible for earlier Medicare entitlement. If this dialysis training or transplant information had not been reported on the initial HCFA-2728-U4, then a second HCFA-2728-U4 should be completed.
4. A second HCFA-2728-U4 need not be completed when a patient changes his/her treatment modality or treatment setting, unless it is to report a transplant or enter a self-dialysis training course during the 3-month qualifying period.
5. We are aware of situations where the Social Security Administration (i.e., local social security offices) requires that HCFA-2728-U4's be completed when an ESRD patient receives a transplant, voluntarily stops dialysis, or regains kidney function. Because the Social Security Administration may be using this form to compute possible termination of Medicare ESRD benefits 36 months after the transplant occurs or 12 months after dialysis stops, the renal transplant and dialysis centers must comply with this requirement. When a HCFA-2728-U4 is completed for this purpose after Medicare entitlement has been established, do not forward copies of the form to the network office. Instead, forward the original and all copies of the form to the local social security office.

CHRONIC RENAL DISEASE MEDICAL EVIDENCE REPORT

IDENTIFYING INFORMATION

1. PATIENT'S NAME (LAST, FIRST, MIDDLE INITIAL)		2. PATIENT'S OWN SOCIAL SECURITY NUMBER	
3. PATIENT'S ADDRESS (STREET, CITY, STATE, ZIP)		4. PATIENT'S CLAIM NUMBER	
5. PHONE NO. *	6. DATE OF BIRTH	7. RACE * <input type="checkbox"/> a. AMERICAN INDIAN OR ALASKAN NATIVE <input type="checkbox"/> b. ASIAN OR PACIFIC ISLANDER <input type="checkbox"/> c. BLACK <input type="checkbox"/> d. WHITE <input type="checkbox"/> e. UNKNOWN	
8. ADDRESS OF SOCIAL SECURITY OFFICE	9. PATIENT'S SEX * <input type="checkbox"/> a. MALE <input type="checkbox"/> b. FEMALE	10. PRIMARY DIAGNOSIS (CAUSE OF ESRD) **	
11. NAME, ADDRESS, AND PHONE NUMBER OF PHYSICIAN RESPONSIBLE FOR RENAL TREATMENT AT TIME OF CLAIM			

TREATMENT INFORMATION—DIALYSIS

TYPE OF DIALYSIS	DATE REGULAR DIALYSIS BEGAN	FREQUENCY SINCE REGULAR DIALYSIS BEGAN (TIMES PER WEEK)	HAS DIALYSIS ENDED?	IF ENDED, DATE OF LAST DIALYSIS
12a <input type="checkbox"/> HEMODIALYSIS	12b.	12c.	12d <input type="checkbox"/> YES <input type="checkbox"/> NO	12e.
13a <input type="checkbox"/> PERITONEAL <input type="checkbox"/> CAPD <input type="checkbox"/> CCPD	13b.	13c.	13d <input type="checkbox"/> YES <input type="checkbox"/> NO	13e.
14 NAME OF DIALYSIS PROVIDER			15 DIALYSIS PROVIDER NUMBER	

TREATMENT INFORMATION—TRANSPLANT

16. DATE(S) OF TRANSPLANT		17. NAME OF TRANSPLANT HOSPITAL		18 PROVIDER NO
19 WAS THE PATIENT ADMITTED AS AN INPATIENT TO A HOSPITAL IN PREPARATION FOR, OR ANTICIPATION OF, A KIDNEY TRANSPLANT PRIOR TO THE DATE OF ACTUAL TRANSPLANTATION? <input type="checkbox"/> YES <input type="checkbox"/> NO		20. IF YES, ENTER DATE(S)	21. NAME OF HOSPITAL FOR ITEM 19	22 PROVIDER NO.
23. CURRENT STATUS OF TRANSPLANT (IF b. CHECKED, ANSWER 24 OR EXPLAIN IN REMARKS) <input type="checkbox"/> a. FUNCTIONING <input type="checkbox"/> b. REJECTED		24 DATE OF RETURN TO REGULAR DIALYSIS	25 CURRENT TREATMENT SITE <input type="checkbox"/> a. HOME <input type="checkbox"/> b. FACILITY	

MEDICAL CERTIFICATION

26. DO YOU CERTIFY THAT THIS PATIENT HAS REACHED THE STATE OF RENAL IMPAIRMENT THAT APPEARS IRREVERSIBLE AND PERMANENT AND REQUIRES A REGULAR COURSE OF DIALYSIS OR KIDNEY TRANSPLANTATION TO MAINTAIN LIFE? <input type="checkbox"/> YES <input type="checkbox"/> NO	SIGNATURE AND TITLE OF ATTENDING PHYSICIAN	DATE
--	--	------

CERTIFICATION OF SELF CARE DIALYSIS TRAINING

27 NAME ADDRESS OF TRAINING PROVIDER	PROVIDER NO	28 DATE TRAINING BEGAN	29 TYPE OF TRAINING <input type="checkbox"/> a. HEMODIALYSIS <input type="checkbox"/> b. IPD <input type="checkbox"/> c. CAPD <input type="checkbox"/> d. CCPD
30 HAS THE PATIENT COMPLETED THE TRAINING PROGRAM? <input type="checkbox"/> YES <input type="checkbox"/> NO	IF NO, WHEN IS THE PATIENT EXPECTED TO COMPLETE THE PROGRAM?		31. DO YOU CERTIFY THAT THE PATIENT IS EXPECTED TO COMPLETE TRAINING SUCCESSFULLY AND SELF DIALYZE ON A REGULAR BASIS? <input type="checkbox"/> YES <input type="checkbox"/> NO
32. I CERTIFY THAT THE ABOVE SELF-DIALYSIS TRAINING INFORMATION IS BASED ON CONSIDERATION OF ALL PERTINENT MEDICAL, PSYCHOLOGICAL, AND SOCIOLOGICAL FACTORS AS REFLECTED IN RECORDS KEPT BY THIS TRAINING FACILITY, AND IS CORRECT.			
SIGNATURE OF PHYSICIAN PERSONALLY FAMILIAR WITH THE PATIENT'S TRAINING	TITLE	DATE	
33 REMARKS			

34 I HEREBY AUTHORIZE ANY PHYSICIAN, HOSPITAL, AGENCY, OR OTHER ORGANIZATION TO DISCLOSE TO THE SOCIAL SECURITY ADMINISTRATION FOR PURPOSES OF REVIEWING MY APPLICATION FOR MEDICARE ENTITLEMENT UNDER THE SOCIAL SECURITY ACT, ANY MEDICAL RECORDS OR OTHER INFORMATION ABOUT MY MEDICAL CONDITION

SIGNATURE OF PATIENT (SIGNATURE BY MARK MUST BE WITNESSED)

DATE

INSTRUCTIONS FOR COMPLETING THE
CHRONIC RENAL DISEASE MEDICAL EVIDENCE REPORT, HCFA-2728-U4

ITEM	PROCEDURE
1	<u>Patient's Name (Last, First, Middle Initial)</u> (To be completed by the patient or someone acting for the patient.) Enter the patient's name (last, first, middle initial).
2	<u>Patient's Own Social Security Number</u> (To be completed by the patient or someone acting for the patient.) Enter the patient's own social security number.
3	<u>Patient's Address (Street, City, Zip)</u> (To be completed by the patient or someone acting for the patient.) Enter the patient's mailing address (number and street, city, state, and zip code).
4	<u>Patient's Claim Number</u> (To be completed by the patient or someone acting for the patient.) If the patient is a recipient of monthly social security benefits, enter the claim number (social security number and appropriate suffix) on which he or she is entitled.
5	<u>Phone No.</u> (To be completed by the patient or someone acting for the patient.) Enter the patient's home telephone number.
6	<u>Date of Birth</u> (To be completed by the patient or someone acting for the patient.) Enter patient's date of birth.
7	<u>Race</u> (To be completed by the patient or someone acting for the patient.) Check the appropriate block to identify race. Definitions of the basic racial categories for Federal statistics are as follows:

- a. American Indian or Alaskan Native: A person having origins in any of the original peoples of North America, and who maintains cultural identification through tribal affiliation or community recognition.
- b. Asian or Pacific Islander: A person having origins in any of the original peoples of the Far East, Southeast Asia, the Indian subcontinent, or the Pacific Islands. This area includes, for example, China, India, Japan, Korea, the Philippine Islands, and Samoa.
- c. Black: A person having origins in any of the black racial groups of Africa.
- d. White: A person having origins in any of the original peoples of Europe, North Africa, or the Middle East.
- e. Unknown: Check this block if race is unknown.

8

Address of Social Security Office

(To be completed by social security office.)
Enter the address of the social security office servicing the claim.

9

Patient's Sex

(To be completed by the patient or someone acting for the patient.) Check the appropriate block to identify sex.

10

Primary Diagnosis (Cause of ESRD)

(To be completed by the physician supervising the patient's kidney treatment or someone acting for the physician.) Enter the primary diagnosis (narrative and ICD9CM code) established at the time it was determined that the patient required dialysis treatment (i.e., primary diagnosis causing ESRD). (See Appendix for a list of acceptable entries for this item.)

- 11 Name, Address, and Phone Number of
Physician Responsible for Renal Treatment at
Time of Claim
(To be completed by the patient or someone
acting for the patient.) Enter the name,
office address, and telephone number of the
physician who is supervising the patient's renal
treatment.
- 12a Type of Dialysis--Hemodialysis
(To be completed by the physician supervising
the patient's kidney treatment or someone
acting for the physician.) If the patient is, or
was, on regular hemodialysis, check this block
and complete items 12b through 12e.
- 12b Date Regular Dialysis Began
(To be completed by the physician supervising
the patient's kidney treatment or someone
acting for the physician.) Enter the date
(month, day, year) the patient began a regular
course of dialysis.
- 12c Frequency Since Regular Dialysis Began
(To be completed by the physician supervising
the patient's kidney treatment or someone
acting for the physician.) Enter the number of
times per week the patient undergoes dialysis.
- 12d Has Dialysis Ended?
(To be completed by the physician supervising
the patient's kidney treatment or someone
acting for the physician.) Check the
appropriate block to indicate whether or not
the patient has ended a regular course of
dialysis.
- 12e If Ended, Date of Last Dialysis
(To be completed by the physician supervising
the patient's kidney treatment or someone
acting for the physician.) If item 12d is "Yes,"
enter the date (month, day, year) that the last
dialysis treatment was given/received.

- 13a Type of Dialysis--Peritoneal, CAPD, or CCPD
(To be completed by the physician supervising the patient's kidney treatment or someone acting for the physician.) If the patient is, or was, on regular peritoneal dialysis (i.e., intermittent peritoneal dialysis), CAPD (continuous ambulatory peritoneal dialysis), or CCPD (continuous cycling peritoneal dialysis), check this block and complete items 13b through 13e.
- 13b Data Regular Dialysis Began
(To be completed by the physician supervising the patient's kidney treatment or someone acting for the physician.) Enter the date (month, day, year) the patient began a regular course of dialysis.
- 13c Frequency Since Regular Dialysis Began
(To be completed by the physician supervising the patient's kidney treatment or someone acting for the physician.) Enter the number of times per week the patient undergoes dialysis. If the patient is on CAPD or CCPD, multiply the number of treatments/exchanges per day times 7 days, and enter the product.
- 13d Has Dialysis Ended?
(To be completed by the physician supervising the patient's kidney treatment or someone acting for the physician.) Check the appropriate block to indicate whether or not the patient has ended a regular course of dialysis.
- 13e If Ended, Date of Last Dialysis
(To be completed by the physician supervising the patient's kidney treatment or someone acting for the physician.) If item 12d is "Yes," enter the date (month, day, year) that the last dialysis treatment was given/received.
- 14 Name of Dialysis Provider
(To be completed by the physician supervising the patient's kidney treatment or someone acting for the physician.) Enter the name of the dialysis facility.

- 15 Dialysis Provider Number
(To be completed by the physician supervising the patient's kidney treatment or someone acting for the physician.) Enter the 6-digit Medicare identification code of the dialysis facility.
- 16 Date(s) of Transplant
(To be completed by the physician supervising the patient's kidney treatment or someone acting for the physician.) Enter the date(s) of the patient's kidney transplant(s).
- 17 Name of Transplant Hospital
(To be completed by the physician supervising the patient's kidney treatment or someone acting for the physician.) Enter the name of the hospital the patient entered for the dates in item 16.
- 18 Provider No.
(To be completed by the physician supervising the patient's kidney treatment or someone acting for the physician.) Enter the provider number (6-digit Medicare identification code) of the transplant hospital identified in item 17.
- 19 Was the Patient Admitted as an Inpatient to a Hospital in Preparation for, or Anticipation of, a Kidney Transplant Prior to the Date of Actual Transplantation?
(To be completed by the physician supervising the patient's kidney treatment or someone acting for the physician.) Check the appropriate block to indicate whether or not (prior to the month of transplant) the patient was in a hospital for transplant or for necessary procedures preliminary to transplant.
- 20 If Yes, Enter Date(s)
(To be completed by the physician supervising the patient's kidney treatment or someone acting for the physician.) If the answer to item 19 was "yes," enter the date(s) of hospitalization.

- 21 Name of Transplant Hospital for Item 19
(To be completed by the physician supervising the patient's kidney treatment or someone acting for the physician.) Enter the name of the hospital for item 19.
- 22 Provider No.
(To be completed by the physician supervising the patient's kidney treatment or someone acting for the physician.) Enter the provider number for the hospital named in Item 21.
- 23 Current Status of Transplant
(To be completed by the physician supervising the patient's kidney treatment or someone acting for the physician.) Check the block which indicates the current status of the transplant. If 23b is checked, item 24 must be completed or explanation must appear in remarks.
- 24 Date of Return to Regular Dialysis
(To be completed by the physician supervising the patient's kidney treatment or someone acting for the physician.) If the transplant rejected, enter the date the patient began a regular course of dialysis.
- 25 Current Treatment Site
(To be completed by the physician supervising the patient's kidney treatment or someone acting for the physician.) Check the appropriate block to indicate whether the patient is a home or in-unit dialysis patient.
- 26 Do You Certify that this Patient Has Reached the State of Renal Impairment . . . ?
(To be signed by the physician supervising the patient's kidney treatment.) This medical certification question must be answered by the physician, and his/her signature and title must appear in this item. Enter the date signed.
- 27 Name and Address of Training
Provider/Provider Number
(To be completed by the physician familiar with the patient's self-care dialysis training or someone acting for the physician.) Enter the name, address, and provider number of the provider furnishing self-care dialysis training.

This item is to be completed if the patient is applying for a waiver of the qualifying period for dialysis based on participation in self-care dialysis training.

28

Date Training Began

(To be completed by the physician familiar with the patient's self-care dialysis training or someone acting for the physician.) Enter the date self-dialysis training began. This item is to be completed if the patient is applying for a waiver of the qualifying period for dialysis based on participation in self-care dialysis training.

29

Type of Training

(To be completed by the physician familiar with the patient's self-care dialysis training or someone acting for the physician.) Check the appropriate block which describes the type of self-care dialysis training the patient began. This item is to be completed if the patient is applying for a waiver of the Medicare qualifying period based on participation in self-care dialysis training.

30

Has the Patient Completed the Training Program?

(To be completed by the physician familiar with the patient's self-care dialysis training or someone acting for the physician.) Check the appropriate block as to whether or not the patient has completed the training program. If the answer is "No," enter the date the patient is expected to complete the training program. This item is to be completed if the patient is applying for a waiver of the Medicare qualifying period based on participation in self-care dialysis training.

31

Do You Certify that the Patient Is Expected to Complete Training...?

(To be completed by the physician familiar with the patient's self-care dialysis training or someone acting for the physician.) Check the appropriate block as to whether or not the physician certifies that the patient is expected to complete the training successfully and self-dialyze on a regular basis. This item is to be

completed if the patient is applying for a waiver of the qualifying period for dialysis based on participation in self-care dialysis training.

32

I Certify that the Above Self-Dialysis Training Information is Based . . .

(To be signed by the physician familiar with the patient's self-care dialysis training.) This certification of self-care dialysis training must be signed by the physician personally familiar with the patient's training. The physician's title and the date signed should also be entered. This item is to be completed if the patient is applying for a waiver of the Medicare qualifying period based on participation in self-care dialysis training.

33

Remarks

Use this space for explanations of answers to other items on the report or for furnishing additional information such as the date of a scheduled transplant.

34

I Hereby Authorize Any Physician, Hospital, Agency, or Other Organization to Disclose to the SSA . . .

The patient's signature authorizing the release of information to the Social Security Administration must be secured here. The date signed must also be entered.

ESRD Facility Survey, HCFA-2744

The ESRD Facility Survey is completed annually by all Medicare-approved renal providers. The survey period is January 1 through December 31. These forms are mailed to the providers by the network offices. Upon completion, the form is returned to the network office.

END STAGE RENAL DISEASE MEDICAL INFORMATION SYSTEM
ESRD FACILITY SURVEY

FOR THE PERIOD

PATIENT/DIALYSIS-EDITS

Fields 01 + 02 = field 03
 Fields 03 + (04A thru 07B) - (08A thru 13B) = field 26
 Sum of fields 14 thru 19 = field 20
 Sum of fields 21 thru 24 = field 25
 Fields 20 + 25 = field 26
 Sum of fields 27 thru 29 = field 26

PART ONE - DIALYSIS

DIALYSIS
PATIENTS

Patients Receiving Care Beginning of Survey Period		
In-Unit	Home	Total Fields 01 thru 02

01 02 03

Additions During Survey Period				
Started for first time ever	Restarted	Trans- ferred from other dialysis unit	Returned after transplan- tation	

04A 05A 06A 07A
04B 05B 06B 07B

Losses During Survey Period					
Deaths	Recov- ered kidney function	Received Trans- plant	Trans- ferred to other dial- ysis unit	Dis- continued dialysis	Other (LTFU)

08A 09A 10A 11A 12A 13A
08B 09B 10B 11B 12B 13B

Patients Receiving Care at End of Survey Period											
Outpatient Dialysis		Self-Dialysis Training				Total Outpatient Dialysis	Home Dialysis				Total Home Dialysis
Hemo- Dialysis	IPD	Hemo- Dialysis	IPD	CAPD	CCPD	Fields 14 thru 19	Hemo- Dialysis	IPD	CAPD	CCPD	Fields 21 thru 24

14 15 16 17 18 19 20 21 22 23 24 25

Total Patients
Fields 20 and 25

26

Patient Eligibility Status End of Survey Period		
Currently enrolled in Medicare	Medicare applica- tion pending	Non- Medicare

27 28 29

Self-Dialysis Patients Completing Training			
Hemo- Dialysis	IPD	CAPD	CCPD

30 31 32 33

Transient Patients	
Treated during survey period	Number of outpatient treatments during survey period

34 35

TREATMENT LOAD

Outpatient Dialysis Treatments	
Hemodialysis	IPD

36 37

Dialysis Training Treatments			
Hemo- dialysis	IPD	CAPD	CCPD

38 39 40 41

COMPLETED BY (Signature)

DATE

TITLE

TELEPHONE NO.

VERIFIED BY (Signature)

DATE

TITLE

REMARKS REGARDING INFORMATION PROVIDED ON THIS SURVEY SHOULD BE ENTERED ON THE LAST PAGE OF THIS SURVEY.

This report is required by law (42 USC 426; 42, CFR 405.2133). Individually identifiable patient information will not be disclosed except as provided for in the Privacy Act of 1974 (5 USC 5520; 45 CFR, Part 5a).

Form HCFA-2744 (11-88)

Department of Health and Human Services
Health Care Financing Administration

END STAGE RENAL DISEASE MEDICAL INFORMATION SYSTEM
ESRD FACILITY SURVEY

FOR THE PERIOD

PATIENTS/TRANSPLANTS-EDITS

Sum of fields 43 thru 46 = field 42

Sum of fields 47 thru 49 = field 50

Field 73 equal to or greater than field 49

Fields 77 + 78 = field 76

PART TWO - KIDNEY TRANSPLANTS

PATIENTS TRANSPLANTED
AND DONOR TYPE

Patients who received transplant at this facility		

42

Eligibility Status of Patients Transplanted at this Facility During the Survey Period							
Currently enrolled in Medicare	Medicare application pending	Non-Medicare					
		U.S. Res.	Other				

43

44

45

46

Transplants Performed at This Facility			
Living Related Donor	Living Unrelated Donor	Cadaveric Donor	Total Fields 47 thru 49

47

48

49

50

Patients Awaiting Transplant			
Dialysis		Non-dialysis	

51

52

CADAVER KIDNEYS

Source of Cadaver Kidneys	Disposition of Cadaver Kidneys				
	Transplanted at this facility	Sent to another U.S. facility	Sent Outside the U.S.	Non-Viable kidneys	Total
Harvested at this center	53	54	55	56	57
Obtained from another transplant hospital	58	59	60	61	62
Obtained from Independent OPOs	63	64	65	66	67
Obtained from non-transplant hospital	68	69	70	71	72
Total	73	74	75	76	

Total Non-Viable Kidneys			
Used for Research		Discarded Kidneys	

77

78

COMPLETED BY (Signature)

DATE

TITLE

TELEPHONE NO.

VERIFIED BY (Signature)

DATE

TITLE

REMARKS REGARDING INFORMATION PROVIDED ON THIS SURVEY SHOULD BE ENTERED ON THE LAST PAGE OF THIS SURVEY

This report is required by law (42 USC 426; 42, CFR 405.2133). Individually identifiable patient information will not be disclosed except as provided for in the Privacy Act of 1974 (5 USC 5520; 45 CFR, Part 5a).

END STAGE RENAL DISEASE MEDICAL INFORMATION SYSTEM
ESRD FACILITY SURVEY

FOR THE PERIOD

PART THREE

REMARKS:

COMPLETED BY (Signature)	DATE	TITLE	TELEPHONE NO.
VERIFIED BY (Signature)	DATE	TITLE	

REMARKS REGARDING INFORMATION PROVIDED ON THIS SURVEY SHOULD BE ENTERED ON THE LAST PAGE OF THIS SURVEY

This report is required by law (42 USC 426; 42, CFR 405.2133). Individually identifiable patient information will not be disclosed except as provided for in the Privacy Act of 1974 (5 USC 5520; 45 CFR, Part 5a).

ESRD FACILITY SURVEY
INSTRUCTIONS FOR COMPLETION

REPORTING RESPONSIBILITY

The ESRD Facility Survey is designed to capture only a limited amount of information concerning each Federally approved renal facility's operation. It is not intended to yield information on the full range of ancillary services or activities, e.g., referrals, graft outcome, etc. These concerns are more appropriately and validly addressed by the network in supplemental requests or through other segments of the Program Management and Medical Information System.

Every facility/center certified by Medicare to provide services to ESRD patients must furnish the information requested in the ESRD Facility Survey (42 USC 426; 20 CFR 405, Section 2133). It is also the facility's/center's responsibility to provide patient and treatment counts to their local ESRD Network upon termination of operations. Facilities certified as inpatient only are not requested to complete a survey.

Survey Period

The Facility Survey is completed annually. The survey period is January 1 through December 31.

This Facility Survey is to be completed for the period January 1, 1988 through December 31, 1988. Unless specified otherwise, all data entered on the Facility Survey is to cover the entire survey period. The form should be completed and forwarded to the local ESRD Network, at the following address:

GENERAL INSTRUCTIONS

For purposes of this document, the word "facility" will be used interchangeably when referring to renal dialysis facilities, renal dialysis centers, or renal transplant centers, as applicable.

All patient and treatment counts requested are to include only the diagnosed chronic ESRD population; no reversible failure patients or treatments may be counted.

All diagnosed chronic ESRD patients treated at the facility should be counted and reported as (1) regular, continuing caseload (field 03); (2) added to the regular caseload (fields 04A through 07B); (3) lost from the regular caseload (fields 08A through 13B); or (4) transient (field 34).

Transient, seasonal, temporary transfers for inpatient care or vacation are reported in two ways. The usual (6 months, 51 percent or more of treatment/supervision) facility counts the patient as part of regular caseload; the facility that treats/supervises the patient episodically (less than 6 months or less than 51 percent) counts the patient (one time only if multiple transfers have occurred) in field 34.

Inclusion of patients in counts should not depend on entitlement determination; newly diagnosed chronic unit admissions should be included, both for peritoneal or hemodialytic therapy and transplantation.

PART ONE

(FOR COMPLETION BY DIALYSIS UNITS ONLY)

PATIENT LOAD

Patients Receiving Care Beginning of Survey Period

Field 01: In-Unit. Enter the number of patients dialyzing in your facility at the beginning of the survey period. This number should reflect your "permanent" patient population; that is, those patients for whom your facility had ongoing medical responsibility for the routine care of the patient until he/she was formally transferred elsewhere. Therefore, this number should include those of your routine patients who were hospitalized or were in transient status away from your facility at the beginning of the survey period. (This number should be the same as that reported in field 22 from the previous survey submitted.) The facility which has the major medical responsibility is the facility which provides in-center backup dialysis, performs necessary medical follow-ups and provides the patient with home dialysis supplies.

Field 02. Home Enter the number of patients followed by your facility (that is, for whom your facility had the major medical responsibility) who were dialyzing at home (hemodialysis, intermittent peritoneal dialysis, continuous ambulatory peritoneal dialysis, or continuous cycling peritoneal dialysis) at the beginning of the survey period. (This number should be the same as that reported in field 27 from the previous survey submitted.) A home patient can only be counted by one (1) facility.

Field 03: Total. Enter the sum of fields 01 and 02. This is to equal the number of patients on your facility's register at the beginning of the survey period. (This number should be the same as that reported in field 28 from the previous survey submitted.)

Additions During the Survey Period

NOTE: This section requires counts for additional in-unit and home dialysis patients accepted during the survey period. **A PATIENT SHOULD NOT BE COUNTED IN MORE THAN ONE FIELD** as an addition in fields 04A through 07B. Count them in the field which describes the last status if more than one is applicable.

Newly Diagnosed Patients:

Field 04A: In-Unit--Started for the First Time Ever. Enter the number of newly diagnosed ESRD patients who were admitted to your facility as chronic maintenance dialysis patients for the first time ever during the survey period. This is a count of patients who have begun their initial course of maintenance dialysis therapy at your facility during the survey period. Do not include patients who transferred to your facility from another dialysis facility; that data is to be reported in field 06A. Include in field 04A patients who began their initial course of maintenance dialysis therapy at a non-approved renal provider and transferred to your facility during the survey period. (That is, patients who were stabilized and then transferred to you.)

Field 04B: Home--Started for First Time Ever. Enter the number of newly diagnosed ESRD patients who, after being stabilized on dialysis, successfully completed a course of self-dialysis training and began home dialysis (their initial course of dialysis after training) during the survey period. If they are still in training at the end of the survey period, report them in field 04A.

Restarted Dialysis:

Field 05A: In-Unit--Restarted. Enter the number of patients who restarted in-unit dialysis during the survey period; e.g., persons who had temporarily recovered kidney function, discontinued dialysis, or had been lost to follow-up and have since restarted routine in-unit dialysis.

Field 05B: Home--Restarted. Enter the number of patients who restarted home dialysis during the survey period. These are patients who had temporarily recovered kidney function, discontinued dialysis, or had been lost to follow-up and have since restarted regular home dialysis.

Transferred From Another Facility:

Field 06A: In-Unit--Transferred from Other Dialysis Unit. Enter the number of patients admitted to your facility who were formally transferred from another facility during the survey period and who are continuing a regular course of dialysis at your facility.

Field 06B: Home--Transferred from Other Dialysis Unit. Enter the number of home patients who were formally transferred by another facility during the survey period to your unit for ongoing medical supervision and responsibility.

Returned After Transplantation:

Field 07A: In-Unit--Returned After Transplantation. Enter the number of patients who returned to in-unit dialysis during the survey period after a transplant failure.

Field 07B: Home--Returned After Transplantation. Enter the number of patients who returned to home dialysis during the survey period after a transplant failure.

Losses During the Survey Period

NOTE: These fields describe losses to your facility of both in-center and home dialysis patients that occurred during the survey period. A PATIENT SHOULD NOT BE COUNTED IN MORE THAN ONE FIELD from field 08A through 13B. For purposes of this survey, "in-unit" includes patients who routinely dialyzed in-unit at the time of loss to the reporting facility, and "home" includes patients who routinely dialyzed at home at the time of loss to the reporting facility. Count patients in the field which describes the last status if more than one is applicable.

Deaths:

Field 08A: In-Unit--Deaths. Enter the number of in-unit dialysis patients who died during the survey period. (These deaths must be shown here by the facility if the patients were reported in fields 01, 04A, 05A, 06A, or 07A.)

Field 08B: Home--Deaths. Enter the number of home dialysis patients who died during the survey period. (These deaths must be shown here by the facility if the patients were reported in fields 02, 04B, 05B, 06B, or 07B.)

Recovered Kidney Function:

NOTE: These are diagnosed chronic renal failure patients who recovered renal function.

Field 09A: In-Unit--Recovered Kidney Function. Enter the number of patients who recovered kidney function and ceased chronic ESRD in-unit dialysis during the survey period.

Field 09B: Home--Recovered Kidney Function. Enter the number of patients who recovered kidney function and ceased chronic home ESRD dialysis during the survey period.

Transplanted:

Field 10A: In-Unit--Received Transplant. Enter the number of patients who received a kidney transplant and left the in-unit dialysis program during the survey period.

Field 10B: Home--Received Transplant. Enter the number of patients who received a kidney transplant and left the home dialysis program during the survey period.

Transferred Out:

Field 11A: In-Unit--Transferred to Other Dialysis Unit. Enter the number of in-unit dialysis patients who permanently transferred to another dialysis facility for their ongoing dialysis during the survey period; that is, those patients whose ongoing, routine medical supervision became the responsibility of another dialysis facility.

Field 11B: Home--Transferred to Other Dialysis Unit. Enter the number of home patients who had been followed by your facility but who are now permanently followed by another home dialysis program.

Discontinued Dialysis:

Field 12A: In-Unit--Discontinued Dialysis. Enter the number of chronic patients who permanently discontinued dialysis (excluding those reported in fields 08A, 09A, 10A and 11A) who had been dialyzing in-unit during the survey period.

Field 12B: Home--Discontinued Dialysis. Enter the number of chronic patients who permanently discontinued dialysis (excluding those reported in fields 08B, 09B, 10B, and 11B) who had been dialyzing at home during the survey period.

Lost to Follow-Up:

Field 13A: In-Unit--Lost to Follow-Up (LTFU). Enter the number of patients who had been dialyzing in-unit who left your dialysis program during the survey period and whose current status is unknown to your facility (lost to follow-up). Do not include those reported in fields 08A, 09A, 10A, 11A, or 12A.

Field 13B: Home--Lost to Follow-Up (LTFU). Enter the number of patients, followed by your facility, who had been dialyzing at home who were removed from your facility's rolls during the survey period, and whose current status is unknown to your facility (lost to follow-up). Do not include those reported in fields 08B, 09B, 10B, 11B, or 12B.

Patient Receiving Care at the End of the Survey Period

NOTE: DO NOT COUNT A PATIENT IN MORE THAN ONE FIELD. Patients receiving care at the beginning of the survey period plus the additions during the survey period minus the losses during the survey period should equal the patients receiving care (remaining) at the end of the survey period. In terms of the survey form, this means that field 03 plus fields 04A through 07B minus fields 08A through 13B equals field 26.

Staff-Assisted Dialysis:

Field 14: Hemodialysis. Enter the number of patients who, at the end of the survey period, were receiving staff-assisted hemodialysis or performing in-unit self hemodialysis.

Field 15: Peritoneal Dialysis. Enter the number of patients who, at the end of the survey period, were receiving staff-assisted intermittent peritoneal dialysis or performing in-unit self peritoneal dialysis.

Self-Dialysis Training:

Field 16: Hemodialysis. Enter the number of patients who are in a self hemodialysis training program as of the end of the survey period. Patients are to be reported in this category only if the training is designed to enable them to perform their own self-dialysis in-unit or at home.

Field 17: Peritoneal Dialysis. Enter the number of patients who are in a self intermittent peritoneal dialysis training program as of the end of the survey period. Patients are to be reported in this category only if the training is designed to enable them to perform their own self-dialysis in-unit or at home.

Field 18: Continuous Ambulatory Peritoneal Dialysis (CAPD). Enter the number of patients who are in a CAPD training program as of the end of the survey period. Patients are to be reported in this category only if the training is designed to enable them to independently perform CAPD.

Field 19: Continuous Cycling Peritoneal Dialysis (CCPD). Enter the number of patients who are in a CCPD training program as of the end of the survey period. Patients are to be reported in this category only if the training is designed to enable them to independently perform CCPD.

Field 20: Total In-Unit. Enter the total number of patients who are in-unit status as of the end of the survey period (the sum of fields 14 through 19).

Home Dialysis

Field 21: Hemodialysis. Enter the number of patients who hemodialyze at home as of the end of the survey period. Patients who are being dialyzed at home with the assistance of staff provided by a dialysis supplier should be counted in this field.

Field 22: Peritoneal Dialysis. Enter the number of patients who are on home intermittent peritoneal dialysis as of the end of the survey period.

Field 23: Continuous Ambulatory Peritoneal Dialysis (CAPD). Enter the number of patients who are on CAPD as of the end of the survey period.

Field 24: Continuous Cycling Peritoneal Dialysis (CCPD). Enter the number of patients who are on CCPD as of the end of the survey period.

Field 25: Total Home: Enter the total number of patients who are home status as of the end of the survey period (the sum of fields 21 through 24).

Total:

Field 26: Total. Enter the total number of patients on your facility's register at the end of the survey period (the sum of fields 20 and 25).

Patient Eligibility Status--End of Survey Period

NOTE: Fields 27 + 28 + 29 should equal the total number of patients at the facility at the end of the survey period (this should be the same number as that in field 26).

Field 27: Currently Enrolled in Medicare. Enter the number of patients at the end of the survey period who were enrolled in Medicare.

Field 28: Medicare Application Pending. Enter the number of patients at the end of the survey period who had Medicare applications pending.

Field 29: Non-Medicare. Enter the number of patients at the end of the survey period who were not enrolled in Medicare and who did not have Medicare applications pending.

Home/Self-Dialysis Patients Completing Training

NOTE: The following section (fields 30 through 33) should be completed only by those facilities that have self-care training programs. Included in this section will be the number of patients who, during the survey period, successfully completed a course of self-dialysis training at the reporting facility which enabled them to self-dialyze in-unit or at home. Patients who were still in a self-dialysis training course on the last day of the survey period are not to be counted in these fields; that data is to be reported in fields 16 through 19. Unsuccessful trainees (those who did not go home or initiate self-care in a facility) are not to be counted here. (This count is a non-add, non-subtract count for caseload purposes.) DO NOT INCLUDE PATIENTS WHO WERE TRANSFERRED TO ANOTHER FACILITY FOR SELF-CARE TRAINING NOR THOSE PATIENTS RETAINED IN SELF-CARE DIALYSIS DURING THE SURVEY PERIOD.

Hemodialysis

Field 30: Hemodialysis. Enter the number of patients who, during the survey period, successfully completed a course of training for home or in-unit self-hemodialysis at your facility.

Peritoneal Dialysis

Field 31: Intermittent Peritoneal Dialysis. Enter the number of patients who, during the survey period, successfully completed a course of training for home or in-unit self-peritoneal dialysis at your facility.

Continuous Ambulatory Peritoneal Dialysis.

Field 32: CAPD. Enter the number of patients who, during the survey period, successfully completed a course of self-dialysis training for continuous ambulatory peritoneal dialysis at your facility.

Continuous Cycling Peritoneal Dialysis.

Field 33: CCPD Enter the number of patients who, during the survey period, successfully completed a course of self-dialysis training for continuous cycling peritoneal dialysis at your facility.

Transient Patients

Field 34: Transient Patients Treated During Survey Period. Enter the number of transient chronic patients who received care at your facility during the survey period. For purposes of this survey, a transient patient is one who does not intend to utilize the reporting facility for ongoing maintenance therapy and is treated less than 6 months of the year. This field is a count of patients, not episodes of treatment. Therefore, if a patient is treated at a facility in February and again at that same facility in March, he/she is counted only once.

Field 35: Transient Patients--Number of Outpatient Treatments During Survey Period. Using the definition of "transient patient" given above, enter the number of transient outpatient dialysis treatments (all dialysis settings) given during the survey period. Be sure to include these treatments in the appropriate modality under treatment load.

TREATMENT LOAD

NOTE: The following section (fields 36 and 37) should reflect only outpatient treatments given to ESRD patients. Self-care training treatments should be reported only in fields 38 through 41. All such treatments, including those provided to transients, should be reported in fields 36 through 41, where appropriate. Please be certain to report treatments to correspond with patients counted at the end of the survey period in a particular modality. Do Not Include Acute Treatments. If a situation occurs where a patient is reported at the end of the survey period but no treatments were provided, please enter in remarks section of the survey as to why treatments were not provided.

Hemodialysis

Field 36: Outpatient Treatments. Enter the number of staff-assisted hemodialysis treatments provided and the number of treatments performed by self dialyzing patients on an outpatient basis during the survey period.

Peritoneal

Field 37: Outpatient Treatments. Enter the number of staff-assisted intermittent peritoneal treatments provided and the number of treatments performed by self dialyzing patients on an outpatient basis during the survey period.

Self-Care Training Treatments

NOTE: These treatment counts should not be included in prior fields 36 and 37. If you report patients completing self-dialysis training, you must report the number of treatments corresponding to the modality of training provided.

Field 38: Hemodialysis. Enter the number of hemodialysis training treatments given during the survey period.

Field 39: Peritoneal Dialysis. Enter the number of intermittent peritoneal dialysis training treatments given during the survey period.

Field 40: CAPD. Enter the number of CAPD training treatments given during the survey period.

Field 41: CCPD. Enter the number of CCPD training treatments given during the survey period.

Signatures

Part One of the Facility Survey requires signatures, as follows:

Completed by:

Enter the date completed and the name, title, and telephone number of the person who completed the Facility Survey for your facility. This person should be the individual who the ESRD network of HCFA can contact to discuss any information provided in the Facility Survey.

Verified by:

Enter the date verified and the signature and title of the facility's renal administrator.

PART TWO

FOR COMPLETION BY TRANSPLANT FACILITIES AND
THEIR RESPECTIVE ORGAN PROCUREMENT AGENCIES

PATIENTS/TRANSPLANTS

Field 42: Patients Who Received Transplant at This Facility. Enter the number of patients who received a kidney transplant at your facility during the survey period. If a patient received more than one transplant at your center during the survey period the patient is to be counted only once. (The figure in field 42 should equal the sum of fields 43 + 44 + 45 + 46.)

Patient Eligibility Status/of Patients Transplanted During Survey Period. Fields 43 through 46 refer to those patients actually transplanted during the survey period. The total of fields 43 through 46 equals the same number reported in field 42.

Field 43: Currently Enrolled In Medicare. Enter the number of patients transplanted during the survey period who were enrolled in Medicare.

Field 44: Medicare Application Pending. Enter the number of patients transplanted during the survey period who had Medicare applications pending.

Field 45: Non-Medicare, U.S. Residents. Enter the number of patients transplanted during the survey period who were not enrolled in Medicare and did not have Medicare applications pending.

Field 46: Non-Medicare, Other. Enter the number of patients transplanted during the survey period who were not enrolled in Medicare, did not have Medicare applications pending, and were neither a U.S. citizen nor a U.S. resident.

Transplants Performed at This Facility:

Field 47: Transplants Performed at This Facility--Living Related Donor. Enter the number of live related donor kidney transplants performed at your center during the survey period.

Field 48: Transplants Performed at This Facility--Living Unrelated Donor. Enter the number of live unrelated donor kidney transplants performed at your center during the survey period.

Field 49: Transplants Performed at This Facility--Cadaveric Donor. Enter the number of cadaveric donor kidney transplants performed at your center during the survey period.

Field 50: Transplants Performed at This Facility--Total Fields 47 and 48. Enter the sum of fields 47 + 48 + 49.

Patients Awaiting Transplant:

Field 51: Patients Awaiting Transplant--Dialysis. Enter the number of current dialysis patients actively awaiting transplant at your center as of the last day of the survey period. These patients must (a) be medically able, (b) have given consent, and (c) be on an active transplant list. This count is limited to individuals awaiting transplant at the reporting center.

Field 52: Patients Awaiting Transplant--Non-Dialysis. Following the procedures described above, enter the number of non-dialysis patients who are awaiting transplant as of the last day of the survey period. This is to include patients scheduled for transplant who have not yet initiated a regular course of dialysis.

CADAVER KIDNEYS

Enter the numbers of cadaver kidneys acquired by your center during the survey period in the appropriate blocks according to their source and disposition. Actual, rather than potential, acquisition is assumed.

Harvested at This Center:

Determine the number of cadaveric kidneys that were harvested at your center during the survey period that were:

Field 53: Transplanted at this center

Field 54: Sent to another U.S. transplant center or an OPO.

Field 55: Sent outside the U.S.

Field 56: Non-viable kidneys, includes kidneys used for research, discarded or unused. See fields 77 and 78.

Field 57: Total of fields 53 through 56.

Cadaveric kidneys procured outside your center by a procurement team from your center are not to be included in these categories.

Obtained from Other Transplant Hospitals:

Determine the number of cadaveric kidneys that were harvested outside your center either at another approved transplant center that were:

Field 58: Transplanted at this center

Field 59: Sent to another U.S. transplant center or an OPO.

Field 60: Sent outside the U.S.

Field 61: Non-viable kidneys, includes kidneys used for research, discarded or unused. See fields 77 and 78.

Field 62: Total of fields 58 through 61.

Obtained from Independent Organ Procurement Organizations:

Determine the number of cadaveric kidneys that were harvested outside your center by an Independent Organ Procurement Organization:

Field 63: Transplanted at this center.

Field 64: Sent to another U.S. center or an OPO.

Field 65: Sent outside U.S.

Field 66: Non-viable kidneys, includes kidneys used for research, discarded or unused. See fields 77 and 78.

Field 67: Total of fields 63 through 66.

Obtained from a Non-Transplant Hospital:

Determine the number of cadaveric kidneys that were harvested outside your center in a hospital not approved by Medicare as a transplant center that were:

Field 68: Transplanted at your center

Field 69: Sent to another U.S. center or an OPO.

Field 70: Sent outside U.S.

Field 71: Non-viable kidneys, includes kidneys used for research, discarded or unused. See fields 77 and 78.

Field 72: Total of fields 68 through 71.

These counts should include, where applicable, any kidneys harvested outside your center by a procurement team from your center.

Disposition of Cadaver Kidneys:

Cadaver Kidneys Transplanted at This Facility:

Field 73: Should equal the total of fields 53 + 58 + 63 + 68. This should be the same number that appears in Field 49. In situations where two kidneys from one cadaveric donor are transplanted to one patient, the total in field 73 can be greater than field 49. When this situation occurs, it should be annotated in Part Three (Remarks).

Cadaveric Kidneys Sent to Another U.S. Facility:

Field 74: Should equal the total of fields 54 + 59 + 64 + 69.

Cadaveric Kidneys Sent Outside U.S.:

Field 75: Should equal the total of fields 55 + 60 + 65 + 70.

Non-Viable Kidneys:

Field 76: Should equal the total of fields 56 + 61 + 66 + 71.

Total Non-Viable Kidneys. Fields 77-78 refer to those kidneys that were non-viable during the survey period. The total of fields 77-78 must equal the same number reported in field 76.

Field 77: Used for Research. Enter the number of kidneys used for research during the survey period.

Field 78: Non-Viable Kidneys. Enter the number of kidneys used for research during the survey period.

Signatures

Part Two of the Facility Survey requires signatures, as follows:

Completed by:

Enter the date completed and the name, title, and telephone number of the person who completed the Facility Survey for your facility. This person should be the individual who the ESRD network or HCFA can contact.

Verified by:

Enter the date verified and the signature and title of the facility's renal administrator.

PART THREE

You may include here any remarks or additional information you wish to supply concerning the information furnished on this survey.

ESRD Transplant Information, HCFA-2745-U4

This form is completed by the transplant provider within 2 weeks following the date of transplant.

Mail the original (PINK) copy and the Information Copy (YELLOW) to the network office. The network will forward the pink copy to the ESRD Support Section and will retain the yellow copy for its files.

The Facility Copy (WHITE) is to be retained by the provider.

Mail the Medicare Specialty Carrier copy (GREEN) to the appropriate Medicare specialty carrier handling claims for immunosuppressive drugs:

If transplant center is east of
Mississippi River, this copy is to be
sent to:

Blue Cross & Blue Shield of
South Carolina
Immuno Drug Processing Unit
2300 Springdale Drive
Camden, South Carolina 29020

If transplant center is west of the
Mississippi River, this copy is to be
sent to:

Transamerica Occidental
Life Insurance Company
Medicare Immuno Drug Claims
Box 54905 Terminal Annex
Los Angeles, California 90054-0905

Form Approved
OMB No. 0938-0064

Transplant Donor

Information is required by law (42 U.S.C. 426, 21 CFR 40.1, Section 2133). Individually identifiable patient information will not be disclosed except as provided for by the Privacy Act of 1974 (5 U.S.C. 552, 45 CFR Part 5a.)

INSTRUCTIONS FOR COMPLETING THE
ESRD TRANSPLANT INFORMATION, HCFA-2745-U4

ITEM	PROCEDURE
1	<p><u>Name (Last, First, Middle Initial)</u></p> <p>Enter the transplant recipient's name (last, first, middle initial). Bold lines separate the last name from the first name, and the first name from the middle initial.</p>
2	<p><u>Date of Birth (Month, Day, Year)</u></p> <p>Enter the transplant recipient's date of birth (month, day, year). Month and day are expressed in 2 digits; e.g., January is 01, November is 11; the first of the month is 01, the fifteenth is 15. The year is expressed by entering the last two digits of the year; e.g., 84 for 1984.</p>
3	<p><u>Health Insurance Claim Number</u></p> <p>Enter the transplant recipient's health insurance claim number. If unable to determine the health insurance claim number, enter the 9-digit social security number.</p>
4a	<p><u>Sex</u></p> <p>Check the box which indicates the sex of the transplant recipient.</p>
4b	<p><u>If Female, Enter Number of Pregnancies</u></p> <p>For the purposes of this form, pregnancy is defined to be synonymous with diagnosed conception. If it was determined that a woman was pregnant and a subsequent abortion occurs, that is to be counted as one pregnancy. As an example, a situation where a woman had a spontaneous abortion and two full-term children would be coded as three pregnancies.</p>
5a	<p><u>Race</u></p> <p>Check the box which describes the race of the transplant recipient. If unknown, check the appropriate box. Definitions of the basic racial</p>

categories for Federal statistics are as follows:

American Indian or Alaskan Native: A person having origins in any of the original peoples of North America, and who maintains cultural identification through tribal affiliation or community recognition.

Asian or Pacific Islander: A person having origins in any of the original peoples of the Far East, Southeast Asia, the Indian subcontinent, or the Pacific Islands. This area includes, for example, China, India, Japan, Korea, and Philippine Islands and Samoa.

Black: A person having origins in any of the black racial groups of Africa.

White: A person having origins in any of the original peoples of Europe, North Africa, or the Middle East.

5b

Ethnicity

Check the box which describes the ethnicity of the transplant recipient as described below:

Hispanic Origin: A person of Mexican, Puerto Rican, Cuban, Central or South American, or other Spanish culture or origin, regardless of race.

Not of Hispanic Origin: A person of culture or origin not described above, regardless of race.

6a

Date of Transplant (Month, Day, Year)

Enter the date the kidney transplant occurred using the day on which circulation was restored to the transplanted kidney. Code the date as explained for item 2.

6b

Transplant Number

Transplant number is defined as the number of

transplants this particular patient has received, including the present transplant. If the recipient has had two previous transplants and this is the third, the box labeled "3rd" must be checked. If this is the recipient's first transplant, the box labeled "1st" must be checked.

6c

If 2, 3, or 4 - Date Preceding Graft Failed

If the recipient is receiving transplant number 2, 3, or 4, (as indicated in item 6b), enter the date the preceding graft(s) failed. The example below shows how to record failure dates for a person who has received his/her third transplant (i.e., two previous transplants have failed):

6a	Date of Transplant (Month, Day, Year)	0	7	1	4	8	8
6b	Transplant Number						
	1 <input type="checkbox"/> 1st						
	2 <input type="checkbox"/> 2nd						
	3 <input checked="" type="checkbox"/> 3rd						
	4 <input type="checkbox"/> 4th or more						
		mo.	yr.				
		1	1	2	8	2	
		2	0	4	8	4	
6c	If 2, 3, or 4 Date preceding graft failed	3					

Note that the graft failure dates are to include only the month and year (not the day) and are to be coded as explained for item 2.

7

Transplant Hospital Provider Number

Enter here the 6-digit renal provider number of the hospital where the transplant was performed.

8

Transplant Surgeon's Name, City, State, Zip Code

Enter the name and office address of the surgeon who performed the renal transplant.

9

Blood Group

Blood group means the appropriate ABO system blood group to which the transplant recipient belongs. Check the box which is appropriate.

10

PRA (Percent Reactive Antibody)

Percent reactive antibody is the percentage of individuals in a cell panel against which the recipient possesses cytotoxic antibodies. The top space is for the highest PRA prior to transplant and the bottom space is for the PRA at the time of transplant. The actual value of the PRA must be entered. This percent must be entered as a whole number; if necessary, round to the nearest whole number (e.g., 99.6 = 100). A fraction is not acceptable--it must appear as a percentage. If the PRA is unknown, indicate that in the applicable box. If the response is negative, enter zero (0). (Do not enter B cell data.)

11a

MLC (Mixed Lymphocyte Culture)

The 2-way MLC is performed using untreated cell populations of donor and recipient, while the 1-way test is performed using donor cells which have been treated or irradiated to suppress transformation of the lymphocytes. Complete 1, 2, and 3 according to which method your institution uses (i.e., (a) for 1-way MLC, (b) for 2-way MLC).

1 MLC Indicate whether MLC was performed 1-way or 2-way. If MLC not done, check the box "not done."

2 Stim. Index Indicate the results in the appropriate box for 1-way or 2-way.

3 Relative Response Indicate the results in the appropriate box for 1-way or 2-way.

11b

HLA Haplotyped☐

Yes

☐

No

HLA (human leucocyte antigen) refers to the antigens identified from tissue typing the recipient which will be compared to determine the number of antigens common to both donor and recipient. Indicate in the appropriate box whether or not the recipient was haplotyped.

If an antigen was not detected, leave a dash (-). If typing not done, leave blank. Only one number per square may be entered next to the loci. Entries of zero (0) alone are not acceptable.

12a

Nephrectomy

If the transplant recipient underwent a nephrectomy of his/her native kidneys, indicate in the appropriate box the number (one or two) of kidneys removed. If a nephrectomy had been performed earlier and one kidney removed, and a second nephrectomy is performed and the other native kidney removed, report the date of the second nephrectomy and mark the box labeled "two" to indicate that both native kidneys have been removed. If a nephrectomy was not performed, indicate this by checking the box labeled "no."

12b

Date (Month, Day, Year)

If a nephrectomy was performed, enter the date performed (month, day, year) as explained for item 2.

13

Reason(s) for Nephrectomy

If a nephrectomy was performed, check the reason(s) which applies. If the reason is "Other," please specify.

14a

Splenectomy

Check the box which indicates whether or not the transplant recipient underwent a splenectomy.

14b

Date (Month, Day, Year)

If the splenectomy was performed, enter the date it was performed (month, day, year) as explained for item 2.

Indicate in the appropriate box whether or not the transplant recipient had a positive hepatitis B_s antigen. If unknown, check that box. Indicate in the appropriate box whether or not the transplant recipient now has a positive hepatitis B_s antigen. If unknown, check that box. If your facility determines antibody to hepatitis B_s antigen, complete this portion of item 15. Bear in mind that if the antibody is present, it indicates that sometime in the past, the antigen was present. Therefore, "yes" should be checked in "Positive Ever."

CMV (Cytomegalovirus) Status

Indicate whether or not CMV antibody is present, not present, or unknown.

Pre-Transplant Blood Transfusions

A pre-transplant blood transfusion is one administered up to 10 days prior to the transplant (i.e., not administered within 10 days before the date of transplant). Indicate here whether or not the transplant recipient received any pre-transplant blood transfusions. As an example, 15 transfusions would be entered 015.

Frozen Blood

Check this box if the patient received frozen blood only in pre-transplant blood transfusions.

Date of Last Blood Transfusion

Enter the date (month, day, year) of the last pre-transplant blood transfusion.

Transfusions at Time of Transplant

Indicate whether or not blood transfusions were given in the operating room at the time of transplant surgery.

Creatinine Decline Without Dialysis at 1 Week Post Transplant

Indicate in this item whether or not there was creatinine decline greater than 3 milligrams per decilitre without dialysis at 1 week post-transplant. If more than one creatinine is done during the first week post-transplant, enter the most recent. If unknown, please indicate.

20a

Donor

Indicate here whether the kidney donor was cadaveric or living related.

20b

If Cadaveric . . .

If cadaveric, and the donor kidney was removed at the transplant center where the transplant was performed, check the box labeled "local." If cadaveric, and the donor kidney was removed at an institution other than the one where the transplant was performed, check the box labeled "shared."

20c

If Living Related . . .

If the donor was living related, check the appropriate box for two haplotype match (HLA identical), one haplotype match (Haplo identical), no haplotype match (Haplo dissimilar), or identical twin. Only one box may be checked.

21

Sex

Check the box indicating the sex of the donor.

22

Age (Years)

Enter the age (years) of the donor; e.g., age 5 years would be entered

0	5
---	---

 ; age 23 years would be

2	3
---	---

 .

23

Blood Group

Check the appropriate box for the blood group of the donor, as explained for item 9.

24

Race

Check the box which describes the race of the donor, as explained for item 5.

25

Infections at Time of Harvest

For donor, indicate whether or not hepatitis B_s antigen was positive (or unknown); whether or not CMV antibody was present (or presence unknown). If other infections were present in the donor at the time of harvest, specify what they were (see below). If the information is unknown, check that box. If there were none, write the word "none."

If other infections were present in the donor, enter the numerical code, as shown below, on the line following the word "specify."

<u>Code</u>	<u>Infection</u>
1	Positive Sputum Culture--Gram Negative Bacteria
2	Positive Urine Culture--Greater than 10,000 per ml.
3	Positive Urine Culture--Greater than 100,000 per ml.
4	Pneumonia--Gram Positive
5	Pneumonia--Gram Negative
6	Meningitis
7	Bacteremia During Admission
8	All Others

26

Cancer at Time of Harvest

If cancer was present in the donor at time of harvest, check the box indicating whether it was intracranial or extracranial. If cancer was not present, indicate that in the appropriate box.

27

HLA Haplotyped 1 ☐ Yes 2 ☐ No

In the space to the right of the term "HLA", indicate whether or not the donor was haplotyped (as done in item 11b for the recipient). Complete the loci data as explained for item 11b.

28

Renal Function Chemistries at Donor Nephrectomy

Indicate the most recent donor Blood Urea Nitrogen (BUN) and serum creatinine prior to harvest. Round the BUN figure to the nearest whole number.

29

Warm Ischemia Time (Minutes)

Three boxes are available for entering warm ischemia time. Warm ischemia time begins when the blood ceases to flow through the kidney in the living or cadaveric donor. In heart-beating cadavers, this occurs when the renal artery (or aorta) is clamped. Warm ischemia time ends when the flush procedure begins. The time, in minutes, must be entered; e.g., 7 minutes would be shown 0 0 7. If unknown or not applicable, leave blank.

30

Cold Time (Hours, Minutes)

Enter the length of time the living or cadaveric donor kidney was preserved on ice. The first two boxes are for hours; the second two are for minutes; e.g., 1 hour and 25 minutes would be shown as

0	1	2	5
---	---	---	---

; 1 hour would be shown as

0	1	0	0
---	---	---	---

; 45 minutes would be shown as

0	0	4	5
---	---	---	---

. If unknown or not applicable, leave blank.

31

Pulsatile Perfusion Total Time (Hours, Minutes)

Enter the cadaveric donor kidney preservation time on pulsatile perfusion. The first two boxes are for hours; the second two are for minutes. See examples shown for item 30.

32a

Donor Pretreatment

Check the type of donor pretreatment medication administered. If either Mannitol or Lasix are checked, box 2 "Diuretics" must also be checked. Do not check box 4 unless both these drugs were administered.

32b

If 3, 4, or 5 above . . .

Check the box indicating the time prior to harvest the donor received any of the medications described in items 3, 4, or 5 of item 32a.

Signature

The signature of the individual completing the form must appear in the space provided in the lower left-hand portion of the form. Include the person's title, telephone number, and the date the form was completed.

ESRD Transplant Follow-up Form

The transplant center completes the ESRD Transplant Follow-up form at the time the transplant recipient is discharged from the hospital following the transplant surgery, again at 6 months post-transplant, again at 1 year post-transplant, and yearly thereafter (unless the patient dies, the transplanted kidney fails, or the patient is lost-to-follow-up.)

A supply of Transplant Follow-up forms is available at each transplant center for use in completing the form initially, i.e., at the time the patient is discharged following the transplant surgery. The subsequent Transplant Follow-ups are generated by the network offices at the intervals mentioned above. These subsequent Transplant Follow-ups are to be completed by the transplant center unless the patient is followed by a physician other than the transplant surgeon. In such a case, the attending physician at the time the Transplant Follow-up is due to be completed is responsible for completing the form. The transplant center is responsible for notifying the network office of a change in the follow-up physician. That network (i.e., the network in which the transplant was performed) is responsible for ensuring that the Follow-up gets to the appropriate physician for completion, even in situations that cross network boundaries.

Mail the completed Transplant Follow-up form to the network.

NETWORK

DEPARTMENT OF HEALTH AND HUMAN SERVICES

(2) TRANSPLANT SURGEON (3) PROVIDER (4) PATIENT NAME (5) TRANSPLANT FOLLOW-UP (6) FIRST I (7) MEDICARE (8) DATE OF TRANSPLANT (9) TRANSPLANT FOLLOW-UP PERIOD: -----

-----PATIENT STATUS-----		-----GRAFT STATUS-----		-----OTHER-----	
YES	NO	YES	NO	YES	NO
(10) IS PATIENT LIVING AT TIME OF THIS FOLLOW-UP? () ()		(16) WAS DIALYSIS PERFORMED DURING THIS FOLLOW-UP PERIOD? () ()		(23) IMMUNOSUPPRESSIVE THERAPY DURING THIS FOLLOW-UP PERIOD:	
(11) IF NOT LIVING, GIVE DATE OF DEATH: (MO) _ _ (DAY) _ _ (YEAR) _ _		(17) DID GRAFT FAIL DURING THIS FOLLOW-UP PERIOD? () ()		(A) IMURAN (AZATHIOPRINE) () ()	
(12) IS PATIENT LOST TO FOLLOW-UP AT TIME OF THIS FOLLOW-UP? () ()		(18) IF YES, GIVE DATE OF FAILURE: (MO) _ _ (DAY) _ _ (YEAR) _ _		(B) CYTOXAN () ()	
(13) IF LOST TO FOLLOW-UP GIVE DATE LAST SEEN: (MO) _ _ (DAY) _ _ (YEAR) _ _		(19) DATE OF GRAFT FAILURE WAS DETERMINED BY:		(C) PREDNISONE () ()	
		(A) PATIENT RECEIVING AN ADDITIONAL TRANSPLANT () ()		(D) ANTI-THYMOCYTE GLOBULIN () ()	
(14) IF PATIENT IS LIVING, ENTER REHABILITATION CODE FROM TABLE A, ATTACHED: _		(B) PATIENT RETURNING TO REGULAR COURSE OF DIALYSIS () ()		(E) IRRADIATION () ()	
		(C) OTHER () ()		(F) SOLUMEDROL () ()	
(15) WAS THE PATIENT TRANSFERRED TO ANOTHER PHYSICIAN OR DIALYSIS FACILITY? () ()		(20) IF GRAFT FAILED, ENTER CAUSE OF TRANSPLANT FAILURE CODE FROM TABLE B, ATTACHED:		(G) CYCLOSPORIN A () ()	
(A) PHYSICIAN NAME -----		(A) PRIMARY: _ _ _		(H) OTHER: SPECIFY: -----	
(B) PROVIDER NUMBER -----		(B) SECONDARY: _ _ _		(24) WERE THERE EPISODES OF CLINICAL REJECTION DURING THIS FOLLOW-UP PERIOD? () ()	
(C) DATE TRANSFERRED: (MO) _ _ (DAY) _ _ (YEAR) _ _		(21) WAS GRAFT REMOVED DURING THIS FOLLOW-UP PERIOD? () ()		(25) SERUM CREATININE:	
		(22) IF YES, GIVE DATE OF REMOVAL: (MO) _ _ (DAY) _ _ (YEAR) _ _		(A) MAXIMUM READING DURING THIS FOLLOW-UP PERIOD: _ _ _	
				(B) MOST RECENT READING DURING THIS FOLLOW-UP PERIOD: _ _ _	
				(26) REMARKS:	

COMPLETED BY: -----

DATE: -----

THIS FORM CONFORMS WITH CRITERIA IN 5 CFR 1320.7 (K) (1).

TABLE A

REHABILITATION CODES

CODE	DESCRIPTION
1	COMPLETE PHYSICAL AND/OR MENTAL DISABILITY: PATIENT HOSPITALIZED OR ESSENTIALLY BEDRIDDEN AT HOME
2	PATIENT UNABLE TO WORK OR ATTEND SCHOOL
3	PATIENT WORKS OR ATTENDS SCHOOL PART-TIME (LESS THAN 50%)
4	PATIENT WORKS OR ATTENDS SCHOOL PART-TIME (GREATER THAN 50%)
5	PATIENT WORKS OR ATTENDS SCHOOL FULL-TIME BUT AT A LOWER LEVEL OF PERFORMANCE THAN AT PRE-ILLNESS
6	PATIENT WORKS OR ATTENDS SCHOOL FULL-TIME AT PRE-ILLNESS LEVEL OF PERFORMANCE
7	PATIENT IS PHYSICALLY AND MENTALLY ABLE TO WORK OR ATTEND SCHOOL BUT HAS CHOSEN NOT TO
8	PATIENT IS PHYSICALLY AND MENTALLY ABLE TO WORK BUT UNABLE TO FIND WORK
9	UNKNOWN

NOTE: THE TERM "WORK" INCLUDES HOUSEWORK.

TABLE B

CAUSE OF TRANSPLANT FAILURE CODES

CODE	CAUSE	CODE	CAUSE
01	ACUTE REJECTION	16	INADEQUATE GRAFT VASCULATURE
02	CHRONIC REJECTION	17	BLADDER LEAK
03	HYPERACUTE REJECTION (BIOPSY-PROVED)	18	URETERAL LEAK
04	ACCELERATED HUMORAL REJECTION	19	URETERAL OBSTRUCTION
05	PRIMARY NON-FUNCTION	20	RENAL PELVIC OR CORTICAL LEAK
06	RECURRENCE OF ORIGINAL DISEASE (BIOPSY-PROVED)	21(A-G)	STABLE RENAL FUNCTION BUT WITHDRAWAL OF MAINTENANCE IMMUNOSUPPRESSION BECAUSE OF:
07	PAPILLARY NECROSIS	21A	INFECTION
08	PARENCHYMAL ABSCESS	21B	GASTRO-INTESTINAL HEMORRHAGE
09	PARENCHYMAL HEMORRHAGE	21C	VISCERAL PERFORATION
10	LOCAL WOUND INFECTION	21D	MALIGNANCY
11	ARTERIAL HEMORRHAGE	21E	SKELETAL COMPLICATIONS
12	VENOUS HEMORRHAGE	21F	STEROID PSYCHOSIS
13	RENAL VEIN THROMBOSIS	21G	OTHER, SPECIFY: -----
14	RENAL ARTERY THROMBOSIS	22	POOR PATIENT COMPLIANCE WITH MAINTENANCE IMMUNOSUPPRESSION
15	RENAL ARTERY STENOSIS	23	OTHER

INSTRUCTIONS FOR COMPLETING THE ESRD TRANSPLANT FOLLOW-UP FORM

The ESRD Transplant Follow-up form is to be completed initially by the transplant surgeon for each Medicare ESRD patient for whom he/she has performed a renal transplant. Subsequent Follow-up forms are to be completed by the transplant surgeon or other physician (attending physician) knowledgeable of the information requested on the Follow-up form.

Each renal transplant center should have on hand a supply of Transplant Follow-up forms. (These forms can be obtained by calling the local ESRD network or the Health Care Financing Administration.) This supply of forms will facilitate completion of the first, or initial, Transplant Follow-up, which must be done at the time the transplant recipient is discharged from the hospital following the transplant surgery, or at the time the patient dies, if this occurs during the hospital stay.

Each transplant surgeon or other physician (as described in the first paragraph) will receive subsequent Follow-up forms in the mail for specific patients at the times the Follow-ups are due. These forms are to be completed by the transplant surgeon or attending physician and then returned to the network.

After the transplant surgeon completes the Follow-up form for the first time (i.e., when the patient is discharged from the hospital or at the time the patient dies, if this occurs during the hospital stay), he/she (or the transplant coordinator) must sign and date the form, and forward it to the network to which the transplant center belongs. The Follow-up form should be received by the NCC within 2 weeks of the patient's date of discharge from the hospital or date of death, if the patient died during the hospital stay.

The subsequent Transplant Follow-up forms, as stated above, will be sent to the transplant surgeon or other physician by the network. These should be completed, signed, dated, and returned to the network within 2 weeks after they are received by the transplant surgeon or other physician.

Once the completed Transplant Follow-up form is received in the network, the network will add that information to their data base and then send the form to the ESRD Support Section for inclusion in the PMMIS.

When the Follow-up is being completed for the first time on a particular patient, the following identifying information must be entered by the transplant surgeon, or transplant coordinator, in the appropriate space(s) on the first row of the Follow-up form:

Transplant Surgeon

Provider Number

Patient Name (Last, First, Middle Initial)

Medicare Health Insurance Claim (HIC) Number

Date of Transplant

Transplant Follow-up Period

On subsequent Follow-up forms for the same patient, this identifying information will be entered by staff at the network. If an error should appear in this row of data, please draw a line through the erroneous information and insert the correct information above it.

The information supplied under Patient Status, Graft Status, and Other is to be for the follow-up period shown at the end of the first row of the Follow-up form. When the Follow-up form is completed for the first, or initial, time, this follow-up period must be entered by the transplant surgeon or transplant coordinator completing the form. The transplant follow-up period is a 1-digit number, as follows:

Transplant Follow-up PeriodInterval Post-Transplant

1	Date of transplant to date of hospital discharge, or date of death if it occurred during the hospital stay
2	Date of hospital discharge to 6 months post-transplant
3	7 months post-transplant to 1 year post-transplant
4	1 year post-transplant to 2 years post-transplant
5	2 years post-transplant to 3 years post-transplant

and yearly thereafter

All data elements in Patient Status, Graft Status, and Other must be answered. If a particular question does not apply to a specific patient, enter "NA" for "not applicable."

Below is an item-by-item description of how to complete each data element under Patient Status, Graft Status, and Other.

DATA ELEMENTCOMPLETION INSTRUCTIONS

PATIENT STATUS

(10) Is Patient Living At Time of this Follow-up?

If the patient is alive when the Follow-up is completed, check the space under "YES." If the patient is deceased, check the space under "NO."

(11) If Not Living, Give Date of Death
(Mo) ____ (Day) ____ (Yr) ____

If the patient is not living, enter the month, day, and year the patient died, using a 6-digit number; e.g., March 7, 1981 would be shown as (Mo) 0 3 (Day) 0 7 (Yr) 8 1 .

(12) Is Patient Lost to Follow-up at Time of this Follow-up?

If the whereabouts of the patient are unknown to the transplant surgeon or other physician responsible for

follow-up data, the patient is considered "lost to follow-up." In that case, check the space under "YES." Otherwise, check the space under "NO."

(13) If Lost to Follow-up, Give
Date Last Seen:
(Mo) ____ (Day) ____ (Yr) ____

If the patient is lost to follow-up, enter here the 6-digit number representing the date the patient was last seen by the transplant surgeon or other physician completing the Follow-up. Example: November 14, 1982, would be shown (Mo) 11 (Day) 14 (Yr) 82.

(14) If Patient is Living,
Enter Rehabilitation Code
from Table A, Attached:

Attached to or on the reverse of the Follow-up form is Table A, entitled "Rehabilitation Codes." The code number must be entered on the Follow-up unless the patient has died.

(15) Was the Patient
Transferred to Another
Physician or Dialysis
Facility?

(A) Physician Name
(B) Provider Number
(C) Date Transferred

If the patient is no longer followed by the transplant surgeon or original transplant center and is followed by a different physician (perhaps a nephrologist) the name of this physician must be entered in (A). If this physician is associated with a renal provider, that number must be entered in (B). The 6-digit date (Mo, Day, Yr.) that the patient was transferred to this physician/facility is to be entered in (C).

(This physician will then become the person to whom the network will send subsequent Follow-ups for completion. The name of the surgeon who performed the transplant, however, will always be the only name shown at the top of the Follow-up in the row of identifying information.)

GRAFT STATUS

(16) Was Dialysis Performed
During this Follow-up
Period?

If the patient received one or more dialysis treatments during this follow-up period, the space under "YES" must be checked. Otherwise, check the space under "NO."

(17) Did Graft Fail During this Follow-up Period?

If, in the opinion of the transplant surgeon or other physician completing the Follow-up, the graft failed during this follow-up period, check the space under "YES." Otherwise, check the space under "NO."

(18) If Yes, Give Date of Failure
(Mo) ____ (Day) ____ (Yr) ____

If the graft failed during this follow-up period, enter the 6-digit number representing the date the graft failed. This date should be entered as described earlier.

(19) Date of Graft Failure Was Determined by:

If the graft failed during this follow-up period, the method used to reach this determination must be indicated as described below:

(A) Patient Receiving an Additional Transplant

(A) Check "YES" if patient received an additional transplant during the follow-up period. Otherwise, check "NO."

(B) Patient Returning to Regular Course of Dialysis

(B) Check "YES" if patient returned to a regular course of dialysis during the follow-up period. Otherwise, check "NO."

(C) Other

(C) Check "YES" if the date of graft failure was determined by other than (A) or (B) above, and specify in item (26) Remarks the method by which the date of graft failure was determined. Otherwise, check "NO."

(20) If Graft Failed, Enter Cause of Transplant Failure Code from Table B, Attached:

(A) Primary: ____

(B) Secondary: ____

The primary cause of transplant failure means the immediate reason the transplant failed. Attached to or on the reverse of the Follow-up is Table B, entitled, "Cause of Transplant Failure Codes." These are 2-digit codes (e.g., 01, 15). When entering the 2-digit code, use the first two spaces provided (e.g., Code 02 would be shown 0 2 ____). Note, however, that Code 21 is divided into six categories (21A through 21G). The suffix letter must also be entered (e.g., Code 21C would be shown 2 1 C.)

(21) Was Graft Removed During this Follow-up Period?

If the transplanted graft was removed during this follow-up period, check the space under "YES." Otherwise, check the space under "NO."

(22) If Yes, Give Date of Removal:
(Mo) ____ (Day) ____ (Yr) ____

If the transplanted graft was removed during this follow-up period, enter the 6-digit number representing the date it was removed. This date must be entered as described earlier.

OTHER

(23) Immunosuppressive Therapy During This Follow-up Period:

Immunosuppressive therapy given the patient during this follow-up period must be described in this part of the Follow-up. Check the appropriate space under "YES" or "NO" for each drug listed. If immunosuppressive drugs other than those listed were administered during this follow-up period, check "YES" for Other and specify (please print) the name(s)

(A) Imuran (Azathioprine)

(B) Cytosan

(C) Prednisone

(D) Antithymocyte Globulin

(E) Irradiation

(F) Solumedrol

(G) Cyclosporin A

(H) Other: Specify:

(24) Were There Episodes of Clinical Rejection During this Follow-up Period?

The definition of clinical rejection is left largely to the discretion of the physician. In general, a decline in renal function unexplained by obstruction, renal artery stenosis, etc., of sufficient magnitude to require an increase in immunosuppressive drugs is clinical rejection. On the other hand, renal function may deteriorate in some

patients who are not treated with increased amounts of immunosuppressive drugs because of infection, cancer, etc. This should also be considered clinical rejection.

(25) Serum Creatinine

(A) Maximum Reading During this Follow-up

Period: __ __ . __

The maximum (highest) serum creatinine reading during this follow-up period must be entered in the appropriate spaces. This figure should be carried to one decimal place.

(B) Most Recent Reading During this Follow-up

Period: __ __ . __

The most recent serum creatinine reading during this follow-up period must be entered in the appropriate spaces. This figure should be carried to one decimal place.

(26) Remarks

Use this space to enter information, if necessary, for item 19(C). Also, this space may be used to enter additional information on any of the data elements appearing on the Follow-up form.

The person completing the Follow-up form must enter his/her name and the date on appropriate lines at the bottom of the form. Thus, questions about the information provided on the form can be directed to the appropriate individual.

ESRD Death Notification, HCFA-2746

Complete the ESRD Death Notification, HCFA-2746, within 2 weeks of the date of death. If the patient was a dialysis patient, the dialysis facility last responsible for the patient's maintenance dialysis (or home dialysis) must complete this form. If the patient was a transplant patient, the transplant center is responsible for completing this form.

Mail the original (GREEN) copy and the second (YELLOW) copy to the network.

Retain the last (WHITE) copy at the provider.

ESRD DEATH NOTIFICATION

Form Approved
OMB No. 0938-0064

END STAGE RENAL DISEASE MEDICAL INFORMATION SYSTEM

1. PATIENT'S LAST NAME		FIRST	MI	2. HEALTH INSURANCE CLAIM NUMBER																													
PATIENT'S COUNTY OF RESIDENCE*		4. STATE	5. DATE OF BIRTH		6. DATE OF DEATH																												
			Mo. Day Yr.		Mo. Day Yr.																												
7. PROVIDER NAME AND ADDRESS (CITY AND STATE)																																	
8. PROVIDER NUMBER		9. PLACE OF DEATH (Check one)		10. WAS AN AUTOPSY PERFORMED?																													
		1 <input type="checkbox"/> Hospital 3 <input type="checkbox"/> Home 2 <input type="checkbox"/> Dialysis facility 4 <input type="checkbox"/> Other		1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No																													
11. CAUSES OF DEATH (Place number from the List of Causes in the spaces provided).																																	
Primary Cause _____ Secondary Causes _____																																	
LIST OF CAUSES																																	
<table style="width:100%; border: none;"> <tr> <td style="width:25%;">01 Pericarditis (Including cardiac tamponade)</td> <td style="width:25%;">05 Embolism, air</td> <td style="width:25%;">10 Pulmonary infection</td> <td style="width:25%;">17 Withdrawal from dialysis</td> </tr> <tr> <td>02 Myocardial infarction, acute</td> <td>06 Embolism, pulmonary</td> <td>11 Septicemia</td> <td>18 Suicide</td> </tr> <tr> <td>03 Cardiac (Other than 01 or 02)</td> <td>07 GI hemorrhage</td> <td>12 Viral hepatitis</td> <td>19 Accidental death, treatment related (Other than 05)</td> </tr> <tr> <td>04 Cerebrovascular (Including spontaneous subdural hematoma)</td> <td>08 Vascular access hemorrhage</td> <td>13 Infection (Other than 10, 11, or 12)</td> <td>20 Accidental death not treatment related</td> </tr> <tr> <td></td> <td>09 Hemorrhage (Other than 04, 07, or 08)</td> <td>14 Hyperkalemia</td> <td>21 Unknown cause</td> </tr> <tr> <td></td> <td></td> <td>15 Pancreatitis</td> <td>22 Other (Specify in Remarks)</td> </tr> <tr> <td></td> <td></td> <td>16 Malignancy</td> <td></td> </tr> </table>						01 Pericarditis (Including cardiac tamponade)	05 Embolism, air	10 Pulmonary infection	17 Withdrawal from dialysis	02 Myocardial infarction, acute	06 Embolism, pulmonary	11 Septicemia	18 Suicide	03 Cardiac (Other than 01 or 02)	07 GI hemorrhage	12 Viral hepatitis	19 Accidental death, treatment related (Other than 05)	04 Cerebrovascular (Including spontaneous subdural hematoma)	08 Vascular access hemorrhage	13 Infection (Other than 10, 11, or 12)	20 Accidental death not treatment related		09 Hemorrhage (Other than 04, 07, or 08)	14 Hyperkalemia	21 Unknown cause			15 Pancreatitis	22 Other (Specify in Remarks)			16 Malignancy	
01 Pericarditis (Including cardiac tamponade)	05 Embolism, air	10 Pulmonary infection	17 Withdrawal from dialysis																														
02 Myocardial infarction, acute	06 Embolism, pulmonary	11 Septicemia	18 Suicide																														
03 Cardiac (Other than 01 or 02)	07 GI hemorrhage	12 Viral hepatitis	19 Accidental death, treatment related (Other than 05)																														
04 Cerebrovascular (Including spontaneous subdural hematoma)	08 Vascular access hemorrhage	13 Infection (Other than 10, 11, or 12)	20 Accidental death not treatment related																														
	09 Hemorrhage (Other than 04, 07, or 08)	14 Hyperkalemia	21 Unknown cause																														
		15 Pancreatitis	22 Other (Specify in Remarks)																														
		16 Malignancy																															
12. IF A MALIGNANCY WAS PRESENT AT DEATH, INDICATE THE YEAR DIAGNOSED, SITE, AND TYPE OF EACH PRIMARY.																																	
<table style="width:100%; border: none;"> <tr> <td style="width:50%;">1. _____ Yr. _____ Site _____</td> <td style="width:50%;">2. _____ Yr. _____ Site _____</td> </tr> <tr> <td style="text-align: center;">_____ Type _____</td> <td style="text-align: center;">_____ Type _____</td> </tr> </table>						1. _____ Yr. _____ Site _____	2. _____ Yr. _____ Site _____	_____ Type _____	_____ Type _____																								
1. _____ Yr. _____ Site _____	2. _____ Yr. _____ Site _____																																
_____ Type _____	_____ Type _____																																
13. IF DECEASED RECEIVED A TRANSPLANT			14. REMARKS																														
1. Date of most recent transplant Mo. Day Yr.																																	
2. Was kidney functioning (patient off dialysis) prior to death? 1. <input type="checkbox"/> Yes 2. <input type="checkbox"/> No 3. <input type="checkbox"/> Unknown																																	
3. Did transplant patient resume outpatient chronic maintenance dialysis prior to death? 1. <input type="checkbox"/> Yes 2. <input type="checkbox"/> No																																	
			SIGNATURE _____ DATE _____																														

NOTE: *If patient residence is not in a specific county, enter incorporated city or township.
This report is required by law (42, U.S.C. 426; 20 CFR 405, Section 2133). Individually identifiable patient information will not be disclosed except as provided for in the Privacy Act of 1974 (5 U.S.C. 5520; 45 CFR Part 5a).

INSTRUCTIONS FOR COMPLETING THE ESRD DEATH
NOTIFICATION, HCFA-2746

ITEM	PROCEDURE
1	<u>Patient's Last Name, First, and Middle Initial</u> Enter the patient's last name, first name, and middle initial as it appears on the Health Insurance Card or other official SSA notification.
2	<u>Health Insurance Claim Number</u> Enter the patient's health insurance number as it appears on the Health Insurance Card or other official SSA notification.
3	<u>Patient's County of Residence</u> Enter the patient's county of residence. If the patient's residence is not a specific county, enter the incorporated city or township.
4	<u>State</u> Enter the two-letter United States Postal Service abbreviation for State in the space provided; e.g., MD for Maryland, NY for New York.
5	<u>Date of Birth</u> Enter the date in month, day, and year order, using a six-digit number; e.g., 07/02/50, for July 2, 1950.
6	<u>Date of Death</u> Enter the date of death in month, day, and year order, using a six-digit number; e.g., 07/14/84, for July 14, 1984.
7	<u>Provider Name and Address (City and State)</u> Enter the complete name, city, and State in which the provider is located.
8	<u>Provider Number</u> Enter the six-digit Provider Number assigned by

the Health Care Financing Administration.

9

Place of Death

Check the one block which indicates the location of the patient at death. In-transit deaths or dead on arrival (DOA) cases are to be indicated by checking "Other."

10

Was an Autopsy Performed

Check the one block which indicates whether or not the patient has been autopsied.

11

Causes of Death

Select from the list of causes the primary cause of death and the secondary or underlying causes of death and enter the appropriate numbers in the spaces provided. If Item 11-22, "Other," is selected as either a primary or secondary cause of death, specify that cause in the Remarks section, Item 14. Enter all secondary causes in the order of their contribution to death; i.e., cause of greatest contribution to death first space, etc.

12

If a Malignancy was Present at Death

If a malignancy was present at death indicate the year diagnosed, site, and type of each primary. Ten spaces are provided for site and fifteen for type. If the space provided is not sufficient, please abbreviate. Do not enter two characters in one space or use more spaces than are provided. Additional clarifying information may be entered in the Remarks section, Item 14.

13

If Deceased Received a Transplant

If the Deceased had ever received a transplant, complete Items 13-1, 13-2, and 13-3.

1. Date of Most Recent Transplant

Enter the date of the most recent transplant in month, day, and year order using a six-digit number; e.g., 07/14/76, for July 14, 1976. If the day is unknown,

enter "00" as place holders.

2. Was Kidney Functioning Prior to Death
Check the block which indicates whether or not the graft was functioning at the time of death or, if not known, check "Unknown."
3. Did Transplant Patient Resume Outpatient Chronic Maintenance Dialysis Prior to Death
Check the block which indicates whether or not the patient was returned to chronic maintenance dialysis prior to death.

If the deceased had never been transplanted, enter "NA" (not applicable) in Item 13 to indicate that absence of data was not an oversight.

14


Remarks

Enter any additional clarifying information in this space.

Signature

The signature of the patient's physician or the facility representative completing the Death Notification should be entered.

ESRD NETWORKS AS OF JANUARY 1, 1988



- Puerto Rico and Virgin Islands are part of Network 3

- Hawaii, Guam, American Samoa are part of Network 17

0429	AIDS, or HIV infection with specified or malignant neoplasms. Acquired immune deficiency syndrome Acquired immunodeficiency syndrome
0439	AIDS-like syndrome, or HIV infection with other specified manifestations in the absence of either specified secondary infections or malignant neoplasms. AIDS-like disease (illness) (syndrome) AIDS-related complex AIDS-related conditions ARC Pre-AIDS Prodromal-AIDS
0449	HIV infection (disease) (illness), or other HIV infection not classified AAV (disease) (illness) (infection) AIDS-associated retrovirus (disease) (illness) (infection) AIDS-associated virus (disease) (illness) (infection) AIDS-related virus (disease) (illness) (infection) AIDS virus (disease) (illness) (infection) ARV (disease) (illness) (infection) Human immunodeficiency virus (disease) (illness) (infection) Human immunovirus (disease) (illness) (infection) Human T-cell lymphotropic virus-III (disease) (illness) (infection) HTLV-III (disease) (illness) (infection) HTLV-III-LAV (disease) (illness) (infection) LAV (disease) (illness) (infection) LAV/HTLV-III (disease) (illness) (infection) Lymphadenopathy-associated virus (disease) (illness) (infection)
189	Carcinoma, Kidney (Calyx, Hilus and Pelvic)
189	Tumor, Malignant, Kidney
189	Cancer of Kidney (Calyx, Hilus and Pelvic)
189	Malignant Neoplasm of Kidney & other unspecified urinary organs
189	Hypernephroma
2028	Lymphomas
2030	Multiple Myeloma
2030	Light Chain Disease

25000*	Diabetes Type II (unspecified)	*Non-insulin dependent
25001**	Diabetes Type I (unspecified)	**Insulin dependent
25000	Diabetes Mellitus Type II	
25001	Diabetes Mellitus Type I	
25000	DM Type II	
25001	DM Type I	
25000	Diabetes, Adult	
25001	IDDM (Insulin Dependent Diabetes Mellitus)	
25000	NIDDM (Non-insulin Dependent Diabetes Mellitus)	
25001	JODM	
25001	Juvenile Onset Diabetes Mellitus	
25040	Diabetes with renal manifestations Type II	
25041	Diabetes with renal manifestations Type I	
25040	Diabetic Glomerulosclerosis or Diabetic Glomerulosclerosis Type II	
25041	Diabetic Glomerulosclerosis Type I	
25041	Diabetic Nephropathy Type I	
25040	Diabetic Nephropathy Type II	
25040	Glomerulosclerosis, Inter-capillary or Glomerulosclerosis, Inter-capillary Type II	
25041	Glomerulosclerosis, Inter-capillary Type I	
25040	Inter-capillary Glomerulosclerosis or Inter-capillary Glomerulosclerosis Type II	
25041	Inter-capillary Glomerulosclerosis Type I	
25040	Kimmelstiel Wilson Syndrome or Kimmelstiel Wilson Syndrome Type II	
25041	Kimmelstiel Wilson Syndrome Type I	
25041	Kidney Disease of Diabetes Mellitus Type I	
25040	Kidney Disease of Diabetes Mellitus Type II	
2700	Cystinosis, Malignant	
2718	Oxalate Nephropathy	
2718	Oxalosis	
2727	Fabry's Disease	
2741	Gouty Nephropathy	
2741	Urate Nephropathy	
2773	Amyloidosis	
2826	Sickle Cell Disease	
2831	Hemolytic Uremic Syndrome	
2870	Henoch-Schonlein Syndrome	

4010	Malignant Hypertension
4011	Benign Hypertension
4019	Hypertension
4019	Primary Hypertensive Disease
4019	Essential Hypertension
4030	Nephrosclerosis, Malignant
4030	Hypertensive Renal Disease, Malignant
4031	Nephrosclerosis, Benign
4031	Hypertensive Renal Disease, Benign
4039	Nephrosclerosis
4039	Hypertensive Renal Disease
4039	Arteriolar nephrosclerosis
4039	Atherosclerotic Kidney Disease
4039	Hypertensive Nephropathy
4039	Renal Vascular Disease
4039	Atheromatosis Embolic Kidney
4040	Hypertensive Heart and Renal Disease, Malignant
4041	Hypertensive Heart and Renal Disease, Benign
4049	Hypertensive Heart and Renal Disease
4049	Cardiorenal Syndrome
4401	Stenosis, Renal Artery
4431	Buerger's (Berger's) Disease
4460	Polyarteritis, Renal
4460	Renal Polyarteritis
4462	Vasculitis & Its Derivatives
4462	Anti-GBN Glomerulonephritis
4462	Anti-Glomerulobasement Membrane Glomerulonephritis
4462	Goodpasture's Disease (Syndrome)
4464	Granulomatosis
4464	Wegener's Granulomatosis
4464	Wegener's Syndrome
4466	Thrombotic Thrombocytopenic Purpura
4466	TTP
5724	Hepatorenal Syndrome
5800	Glomerulonephritis, Acute
5804	Glomerulonephritis, Acute with lesion of rapidly progressive Glomerulonephritis
5804	RPGN(Rapid Progressive Glomerulonephritis)
58089	Acute Interstitial Nephritis
5800	Acute Glomerulonephritis
5809	Acute Glomerulonephritis with unspecified pathological lesion in kidney

5309	Glomerulonephritis, Acute with unspecified pathological lesion in kidney
5811	Focal Glomerulonephritis
5811	Glomerulonephritis, Focal
5811	Focal Glomerulosclerosis with Nephrotic Syndrome
5819	Nephrotic Syndrome
5819	Nephrosis
5821	Focal Glomerulosclerosis
5821	Glomerulosclerosis, Focal
58289	Chronic Interstitial Nephritis
58289	Hereditary Interstitial Nephritis
58289	Interstitial Nephritis, Hereditary
5829	Chronic Glomerulonephritis
5829	Chronic Glomerulonephritis with unspecified pathological lesion in kidney
5829	Glomerulonephritis, Chronic
5829	Glomerulonephritis, Chronic with unspecified pathological lesion in kidney
5830	Proliferative Glomerulonephritis
5830	Radiation Nephritis
5830	Shunt Nephritis
5831	Membranous Glomerulonephritis
5832	Membranoproliferative Glomerulonephritis
5832	Mesangiocapillary Glomerulonephritis
5837	Nephritis or Nephropathy with Renal Medullary lesion
58381	Nephritis and Nephropathy, not specified as acute or chronic, in diseases classified elsewhere
58389	Analgesic Nephropathy
58389	Other Interstitial Nephritis
58389	Interstitial Renal Disease
5839	Glomerulonephritis
5839	GN
5839	Nephritis
5839	Nephritis or Nephropathy
5839	Bright's Disease
5839	Renal Insufficiency
5839	Nephropathy
5845	Nephrotoxins (various) (specify)
5845	Toxic Nephropathy (specify)
5845	Rhabdomyolysis (X-ray Dye Reaction)
5845	Renal Tubular Disease
586	Renal Failure, Unspecified
586	Chronic Uremia
586	Uremia
587	Glomerulosclerosis
587	Heroin Abuse Nephropathy
589	Small Kidney of Unknown Cause

5900	Chronic Pyelonephritis
5900	Pyelonephritis, Chronic
59080	Pyelonephritis, Unspecified
59080	Necrosis, Renal (Gangrene)
59080	Variations of Tubular Necrosis
5909	Infections of Kidney
591	Hydronephrosis
5920	Calculi (Renal)
5929	Calculi (Urinary)
5920	Staghorn Calculus
5920	Nephrolithiasis
59381	Occlusion, Renal Artery
59381	Thrombosis Renal Artery
59381	Kidney Artery Embolism
59389	Obstructive Kidney
59389	Obstructive Nephropathy
599	Obstructive Uropathy, Acquired
599	Urinary Obstruction (specify)
599	Uropathy, Acquired (Obstructive)
600	Hyperplasia of Prostate
6462	Renal Failure (in pregnancy, childbirth, puerperium)
6954	Lupus Erythematosus
7100	Lupus
7100	SLE
7100	Systemic Lupus Erythematosus
7100	Lupus Nephritis
7101	Scleraderma
7101	Scleroderma
7140	Rheumatoid Arthritis
753	Congenital Anomalies of Urinary System
753	Renal Agenesis and Dysgenesis
7530	Hypoplasia Kidney Disease
7530	Solitary Kidney
7531	Cystic Kidney Disease
7531	Medullary Cystic Kidney Disease
7531	Multicystic Kidney Disease
7531	Polycystic Kidney Disease
7532	Obstructive defects of renal pelvis, and ureter
7533	Calculi Renal, Congenital
7533	Obstructive Uropathy, Congenital
7533	Uropathy, Congenital (Obstructive)
7539	Dysplasia (Anomaly) of Kidney
7598	Alport's Syndrome

7999	Etiology Unknown
7999	Unknown, Etiology
9654	Aromatic Analgesics, Phenacetin (Acetophenetidin)
9659	Analgesic Abuse (specify)
9828	Ethylene Glycol Ingestion
99681	Rejection, Transplant
---	Tumor, Malignant*
---	Carcinoma*
---	Reflux**
---	Obstruction**
---	Collagen Vascular Disease***
---	RTA (Renal Tubular Acidosis)****
*	Tumor, Malignant and Carcinoma without site are unacceptable narrative entries in item 10 of the HCFA-2728. Tumor, Malignant and Carcinoma with specific site narrative is what must be entered and coded in item 10.
**	Reflux and Obstruction are unacceptable narrative entries in item 10 of the HCFA-2728. Specific condition(s)/disease(s) narrative is what must be entered and coded in item 10.
***	Collagen Vascular Disease is an unacceptable narrative entry in item 10 of the HCFA-2728-U4. Collagen Vascular Disease represents one of several conditions (or diseases) in which collagen tissue is involved. The specific condition (or disease) narrative is what must be entered and coded in item 10.
****	RTA (Renal Tubular Acidosis) is an unacceptable narrative entry in item 10 of the HCFA-2728-U4. RTA does not describe a Condition which leads to renal failure.

U.S. Department of
Health and Human Services
Health Care Financing Administration
1A9 Oak Meadows Building
6325 Security Boulevard
Baltimore, Maryland 21207

CMS LIBRARY



3 8095 00000152 5



U.S. Department of Health and Human Services
Health Care Financing Administration
Bureau of Data Management and Strategy
HCFA Pub. No. 03278 February 1989